Tremelimumab

Brand name: Lytogobi

DILI Likelihood

Score C — Probable Hepatotoxin

This drug is probably linked to idiosyncratic liver injury, but has been reported uncommonly and no characteristic signature has been identified.

Fewer than 12 cases without a significant case series.

Classification

Primary class Antineoplastic

Secondary class HCC

FDA approval 2022